Drug Overview
Gilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 1 (HER1), HER2, and HER4. In cancerous cells where EGFR and HER2 receptors are overexpressed, activation of these receptors can trigger cell-signaling pathways that lead to uncontrolled tumor cell proliferation. Gilotrif works by blocking these receptors, preventing their activation and thereby inhibiting the unwanted signaling pathways. Gilotrif irreversibly binds to two key receptors involved in cell proliferation, in comparison to first-generation TKIs which only provide single reversible receptor blocking.
Gilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 1 (HER1), HER2, and HER4. In cancerous cells where EGFR and HER2 receptors are overexpressed, activation of these receptors can trigger cell-signaling pathways that lead to uncontrolled tumor cell proliferation. Gilotrif works by blocking these receptors, preventing their activation and thereby inhibiting the unwanted signaling pathways. Gilotrif irreversibly binds to two key receptors involved in cell proliferation, in comparison to first-generation TKIs which only provide single reversible receptor blocking.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Gilotrif : Non-small cell lung cancer (NSCLC)
Gilotrif : Head and neck cancer
LIST OF FIGURES
Figure 85: Cemiplimab for non-small cell lung cancer – SWOT analysis
Figure 86: The authors drug assessment summary for cemiplimab in non-small cell lung cancer
Figure 87: The authors drug assessment summary for cemiplimab in non-small cell lung cancer
Figure 88: Dacomitinib for non-small cell lung cancer – SWOT analysis
Figure 89: The authors drug assessment summary for dacomitinib in non-small cell lung cancer
Figure 6: The authors drug assessment summary of Gilotrif for SCCHN
Figure 91: Dacomitinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 117: Capmatinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 2: Gilotrif late-phase trial data in non-small cell lung cancer
Table 3: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Gilotrif patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 123: Dacomitinib pivotal trial data in non-small cell lung cancer
Table 6: Gilotrif Phase III trial data in head and neck cancer
Table 7: Gilotrif early-phase data in head and neck cancer
Table 8: Gilotrif patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
